



Legal Division
Patents & Trademarks
D377/AP6A-1

Abbott Laboratories
100 Abbott Park Road
Abbott Park, IL 60064-6008

Telephone: (847) 935-7835
Facsimile: (847) 938-2623

FACSIMILE COVER SHEET

DATE: March 31, 2004

TO: Attn: Examiner David Lukton
United States Patent & Trademark Office

FROM: Kalim S. Fuzail
Patents and Trademarks
D-0377, AP6A-1
Telephone: (847) 935-7835

PHONE NUMBER OF TELECOPY MACHINE: 703-872-9306

TOTAL NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 39

MESSAGE:

Re: U.S. Patent Application No. 09/576,097
Our Ref.: 6499US02

Per your request, attached please find our Amendment dated February 3, 2004. We did send the Response within the time limit. Attached is the postcard certifying receipt by the PTO. Examiner Lukton ask it to be resent because he did not receive it and it may be lost at the PTO.

Thank you,
Kalim Fuzail

THIS TRANSMISSION IS INTENDED ONLY FOR THE INDIVIDUAL(S) TO WHOM IT IS ADDRESSED.

It may contain confidential information, attorney work product, or other privileged material. If you are not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this transmission is strictly prohibited. If you have received this transmission in error, please notify us immediately by telephone at (847) 935-7574 and return the transmission to us at the address listed above.

©Abbott Laboratories, 1991. All rights reserved. IF YOU DO NOT RECEIVE ALL PAGES AS INDICATED, PLEASE CALL (847) 935-7574

6499.US.02

KSF/tmp/PPD

February 3, 2003


Patent Office Mail Room: Will you
please affix the Patent Office Stamp
and return this card to acknowledge
receipt of the following documents:

Applicants: L. Alani, et al.
Serial No.: 09/576,097

Filing Date: May 22, 2000

Title: IMPROVED PHARMACEUTICAL
FORMULATIONS

1. Transmittal Letter
2. Amendment and Response with Marked-up Version, 32 pages
3. Associate Power of Attorney
4. Request for Three-Month Extension of Time, in duplicate
5. Return Receipt Postcard



All mailed to the Patent and Trademark Office by First Class Mail on February 3, 2003.

MAR. 31. 2004 11:26AM

ABBOTT LABS

NO. 3470 P. 3

6499.US.02

KSF/tmp/PPD

February 3, 2003

Patent Office Mail Room: Will you please affix the Patent Office Stamp and return this card to acknowledge receipt of the following documents:

Applicants: L. Alani, et al.
Serial No.: 09/576,097
Filing Date: May 22, 2000
Title: IMPROVED PHARMACEUTICAL FORMULATIONS

1. Transmittal Letter
2. Amendment and Response with Marked-up Version, 32 pages
3. Associate Power of Attorney
4. Request for Three-Month Extension of Time, in duplicate
5. Return Receipt Postcard

All mailed to the Patent and Trademark Office by First Class Mail on February 3, 2003.

FILE

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alani, *et al.*

Serial No.: 09/576,097

Filed: May 22, 2000

For: IMPROVED PHARMACEUTICAL
FORMULATIONS

Case No.: 6499.US.02

Group Art No.: 1653

Examiner: D. Lukton

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit, February 3, 2003

Tanya Parent 2/3/03
Tanya Parent Date

Commissioner for Patents
Washington D.C. 20231

AMENDMENT AND RESPONSE

Dear Sir:

In response to the Office Action dated August 9, 2002, please amend the application as follows:

IN THE CLAIMS

Please amend the claims as follows:

1. (twice amended) A pharmaceutical composition comprising:

- (a) solubilized (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) or a combination of solubilized (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and another HIV protease inhibiting compound, or pharmaceutically acceptable salts thereof, in an amount of from about 1 to about 50 weight % of the composition;
- (b) a pharmaceutically acceptable organic solvent which comprises a medium and/or long chain fatty acid or a mixture thereof in an amount of from about 40 to about 75 weight % of the

US 09/576,097
Amendment and Response
February 3, 2003